BIOLASE, Inc. (NASDAQ:BIOL) Sees Significant Decline in Short Interest

BIOLASE, Inc. (NASDAQ:BIOL) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 592,700 shares, a decrease of 74.1% from the March 31st total of 2,290,000 shares. Based on an average trading volume of 5,510,000 shares, the short-interest ratio is currently 0.1 days. Approximately 1.9% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of BIOLASE in a report on Thursday, April 18th. They issued a “sell” rating for the company.

BIOLASE Price Performance

BIOL remained flat at $0.15 during midday trading on Thursday. 612,965 shares of the company’s stock were exchanged, compared to its average volume of 4,498,681. BIOLASE has a one year low of $0.13 and a one year high of $32.09. The firm has a market cap of $4.81 million, a PE ratio of 0.00 and a beta of 0.67. The company has a quick ratio of 0.68, a current ratio of 1.26 and a debt-to-equity ratio of 34.06. The company’s fifty day moving average price is $0.15 and its 200-day moving average price is $0.83.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. The company had revenue of $13.49 million for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.